机译:Vinorelbine和连续低剂量环磷酰胺作为高风险rhabdomyosarcoma患者的维持化疗(RMS 2005):多期,开放标签,随机,第3期试验
Univ Padua Dept Womens &
Childrens Hlth Haematol Oncol Div Padua Italy;
IRCCS Ist Oncol Veneto IOV Clin Res Unit Padua Italy;
Ctr Leon Berard Inst Hematol &
Oncol Pediat Lyon France;
Hosp Univ Vall Hebron Serv Oncol &
Hematol Pediat Barcelona Spain;
Princess Maxima Ctr Paediat Oncol Utrecht Netherlands;
Royal Manchester Childrens Hosp Dept Paediat Histopathol Manchester Lancs England;
Hop Univ Paris Sud Hop Bicetre AP HP Dept Paediat Surg Paris France;
Gustave Roussy Dept Paediat &
Adolescent Oncol Villejuif France;
PSL Univ Inst Curie SIREDO Oncol Ctr Paris France;
Oslo Univ Hosp Dept Paediat Res Oslo Norway;
Royal Marsden Hosp Children &
Young Peoples Unit Surrey England;
Fondaz IRCCS Ist Nazl Tumori Paediat Oncol Unit Milan Italy;
Univ Padua Dept Womens &
Childrens Hlth Haematol Oncol Div Padua Italy;
Univ Libre Bruxelles Hop Univ Enfants Reine Fabiola Paediat Haematol &
Oncol Brussels Belgium;
Ruth Rappaport Childrens Hosp Rambam Med Ctr Joan &
Sanford Weill Pediat Hematol Oncol &
Bone;
Univ Childrens Hosp Brno Czech Republic;
Inst Nacl Canc Rio De Janeiro Brazil;
Childrens Hosp Wales Dept Paediat Oncol Cardiff Wales;
Fondaz IRCCS Ist Nazl Tumori Paediat Oncol Unit Milan Italy;
机译:Vinorelbine和连续低剂量环磷酰胺作为高风险rhabdomyosarcoma患者的维持化疗(RMS 2005):多期,开放标签,随机,第3期试验
机译:添加剂量加强的多柔比星,用于横纹肌肉瘤的标准化疗(EPSSG RMS 2005):多期,开放标签,随机控制,第3阶段试验
机译:组织型 - 大型软组织Sarcomas患者(ISG-STS 1001)患者的组织型 - 定制Neoadjuvant化疗(ISG-STS 1001)
机译:逆转录病毒介导的人MDR-1转移的第1期试验在接受高剂量化疗和自体干细胞移植的患者中
机译:Sarcome-13 / OS2016试验方案:米法莫肽联合术后化疗的多中心随机开放标签II期试验用于新诊断的高危骨肉瘤患者
机译:Vinorelbine和连续低剂量环磷酰胺作为高风险rhabdomyosarcoma患者的维持化疗(RMS 2005):多期,开放标签,随机,第3阶段试验